gsk0660 and Insulin-Resistance

gsk0660 has been researched along with Insulin-Resistance* in 3 studies

Other Studies

3 other study(ies) available for gsk0660 and Insulin-Resistance

ArticleYear
Polypharmacology of N
    Journal of medicinal chemistry, 2017, 09-14, Volume: 60, Issue:17

    A

    Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Adiponectin; Animals; Cell Line; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Male; Mice; Mice, Inbred C57BL; Polypharmacology; PPAR delta; PPAR gamma; Receptor, Adenosine A3

2017
Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity.
    Journal of hypertension, 2015, Volume: 33, Issue:9

    Endothelial dysfunction plays a key role in obesity-induced risk of cardiovascular disease. The aim of the present study was to analyze the effect of chronic peroxisome proliferator-activated receptor (PPAR)β/δ agonist GW0742 treatment on endothelial function in obese mice fed a high-fat diet (HFD).. Five-week-old male mice were allocated to one of the following groups: control, control-treated (GW0742, 3 mg/kg per day, by oral gavage), HFD, HFD + GW0742, HFD + GSK0660 (1 mg/kg/day, intraperitoneal) or HFD-GW0742-GSK0660 and followed for 11 or 13 weeks. GW0742 administration to mice fed HFD prevented the gain of body weight, heart and kidney hypertrophy, and fat accumulation. The increase in plasma levels of fasting glucose, glucose tolerance test, homeostatic model assessment of insulin resistance, and triglyceride found in the HFD group was suppressed by GW0742. This agonist increased plasma HDL in HFD-fed mice and restored the levels of tumor necrosis factor-α and adiponectin in fat. GW0742 prevented the impaired nitric oxide-dependent vasodilatation induced by acetylcholine in aortic rings from mice fed HFD. Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-α, and interleukin-6 expression, and IκBα phosphorylation found in aortae from the HFD group. GSK0660 prevented all changes induced by GW0742.. PPARβ/δ activation prevents obesity and exerts protective effects on hypertension and on the early manifestations of atherosclerosis, that is, endothelial dysfunction and the vascular pro-oxidant and pro-inflammatory status, in HFD-fed mice.

    Topics: Adiponectin; Adipose Tissue; Animals; Aorta; Blood Glucose; Caveolin 1; Diet, High-Fat; Endothelium, Vascular; Glucose Tolerance Test; Hypertension; Insulin Resistance; Interleukin-6; Male; Mice; Nitric Oxide Synthase Type III; Obesity; PPAR delta; PPAR-beta; Reactive Oxygen Species; Sulfones; Thiazoles; Thiophenes; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Vasodilation

2015
Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.
    Endocrinology, 2010, Volume: 151, Issue:4

    Elevated plasma free fatty acids cause insulin resistance in skeletal muscle through the activation of a chronic inflammatory process. This process involves nuclear factor (NF)-kappaB activation as a result of diacylglycerol (DAG) accumulation and subsequent protein kinase Ctheta (PKCtheta) phosphorylation. At present, it is unknown whether peroxisome proliferator-activated receptor-delta (PPARdelta) activation prevents fatty acid-induced inflammation and insulin resistance in skeletal muscle cells. In C2C12 skeletal muscle cells, the PPARdelta agonist GW501516 prevented phosphorylation of insulin receptor substrate-1 at Ser(307) and the inhibition of insulin-stimulated Akt phosphorylation caused by exposure to the saturated fatty acid palmitate. This latter effect was reversed by the PPARdelta antagonist GSK0660. Treatment with the PPARdelta agonist enhanced the expression of two well known PPARdelta target genes involved in fatty acid oxidation, carnitine palmitoyltransferase-1 and pyruvate dehydrogenase kinase 4 and increased the phosphorylation of AMP-activated protein kinase, preventing the reduction in fatty acid oxidation caused by palmitate exposure. In agreement with these changes, GW501516 treatment reversed the increase in DAG and PKCtheta activation caused by palmitate. These effects were abolished in the presence of the carnitine palmitoyltransferase-1 inhibitor etomoxir, thereby indicating that increased fatty acid oxidation was involved in the changes observed. Consistent with these findings, PPARdelta activation by GW501516 blocked palmitate-induced NF-kappaB DNA-binding activity. Likewise, drug treatment inhibited the increase in IL-6 expression caused by palmitate in C2C12 and human skeletal muscle cells as well as the protein secretion of this cytokine. These findings indicate that PPARdelta attenuates fatty acid-induced NF-kappaB activation and the subsequent development of insulin resistance in skeletal muscle cells by reducing DAG accumulation. Our results point to PPARdelta activation as a pharmacological target to prevent insulin resistance.

    Topics: Analysis of Variance; Animals; Blotting, Western; Carnitine O-Palmitoyltransferase; Cell Line; Cell Nucleus; Electrophoretic Mobility Shift Assay; Epoxy Compounds; Fatty Acids; Humans; Insulin Resistance; Interleukin-6; Mice; Muscle, Skeletal; NF-kappa B; PPAR delta; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfones; Thiazoles; Thiophenes

2010